LEADER 04686nam 2201225z- 450 001 9910557898903321 005 20231214132820.0 035 $a(CKB)5400000000046291 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69010 035 $a(EXLCZ)995400000000046291 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aFibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 electronic resource (276 p.) 311 $a3-03936-784-6 311 $a3-03936-785-4 330 $aFibroblast growth factor (FGF) signal transmission has an essential function in embryonic development and tissue repair, and is dysregulated in the vast majority of malignancies studied. The FGF signaling in the tumor cells is usually increased by autocrine and paracrine mechanisms and gives them a high growth potential, resistance to apoptosis, neoangiogenesis and metastasis, all essential parameters relevant for tumor progression. This makes FGFs, and their tyrosine kinase receptors FGFRs, valuable targets for therapeutic interventions. This book is a collection of 15 recent articles?both original work and reviews?that summarize the current research state effectively. The content covers FGF signaling aspects in gastric, skin, liver, esophageal cancer, melanoma, mesothelioma and glioblastoma, including one article that addresses the role of FGF in the tumor-microenvironment cross-talk. Several reports describe the development of compounds targeting FGFRs, their structure and interaction with the receptor molecules, and their effectivity in preclinical and clinical testing. In summary, the papers demonstrate the complexity of the topic, with various FGF ligands and receptors involved and the need for further research. They also present results that fuel hope that targeting cancer with dysfunctional FGF signaling can become a realistic treatment option. 517 $aFibroblast Growth Factor Receptor 606 $aMedicine$2bicssc 610 $aFGFR4 610 $aFGF19 610 $agene regulation 610 $acancer signaling 610 $aanticancer 610 $aFRS2 610 $aFGFR 610 $aNVP-BGJ398 610 $aLY2874455 610 $asarcoma 610 $acancer-associated fibroblasts 610 $aGPER 610 $abreast cancer 610 $aestrogen 610 $aFGFR1 610 $aFGF2 610 $aoptogenetics 610 $aERK 610 $aAKT 610 $areceptor kinase 610 $aneurite outgrowth 610 $aHEK293 610 $aPC12 610 $afibroblast growth factor receptors 610 $asignaling 610 $areceptor cross-talk 610 $acoreceptor 610 $amembrane proteins 610 $aFGFR2 610 $aERK1/2 610 $aphosphorylation 610 $aserine 610 $anegative feedback loop 610 $acancer 610 $aprognosis 610 $aHCC 610 $ainhibitors 610 $aFGF 610 $afibroblast growth factor 610 $aautocrine signaling 610 $askin 610 $amelanoma 610 $asquamous and basal cell carcinoma 610 $aseborrheic keratosis 610 $atargeted therapy 610 $aresistance 610 $astructure 610 $akinase inhibitor 610 $agastric cancer 610 $amonoclonal antibody 610 $asmall molecule 610 $aFGFR2c 610 $aautophagy 610 $akeratinocyte 610 $aMTOR 610 $aJNK1 610 $areview 610 $amalignant glioma 610 $abrain cancer 610 $aastrocytoma 610 $aSprouty proteins 610 $aFGF-mediated signaling 610 $atumor suppressor 610 $atumor promoter 610 $amalignant pleural mesothelioma 610 $aoverall survival 610 $aimmunohistochemistry 610 $ainfigratinib sensitivity 610 $aFGF8 610 $aFGF18 610 $aadenocarcinoma of the esophagogastric junction 610 $aneoadjuvant therapy 615 7$aMedicine 700 $aHolzmann$b Klaus$4edt$01295512 702 $aMarian$b Brigitte$4edt 702 $aHolzmann$b Klaus$4oth 702 $aMarian$b Brigitte$4oth 906 $aBOOK 912 $a9910557898903321 996 $aFibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor$93023558 997 $aUNINA